Vireo Growth (VREOF) Cost of Revenue (2020 - 2026)
Vireo Growth (VREOF) posted Cost of Revenue of $46.9 million for Q1 2026, down 1.53% sequentially from $47.6 million in Q4 2025, and up 287.6% YoY from $12.1 million in Q1 2025.
Vireo Growth (VREOF) Cost of Revenue (2020 - 2026) Analysis & Trends
Vireo Growth has reported Cost of Revenue for 7 years, with the latest figure at $46.9 million in Q1 2026.
- Quarterly Cost of Revenue rose 287.6% year-over-year to $46.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $176.4 million (up 608.58% YoY) and the FY2025 annual result came in at $141.7 million, up 191.43% from the prior year.
- Cost of Revenue declined to $46.9 million in Q1 2026 per VREOF's latest filing, from $47.6 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $54.3 million in Q3 2025 and troughed at $161782.0 in Q3 2023.
- A 5-year average of $12.5 million and a median of $240322.0 in 2022 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2022 and 2025: Cost of Revenue slumped 99.21% in 2022, then soared 22519.81% in 2025.
- Over 5 years, Cost of Revenue stood at $240322.0 in 2022, then retreated by 25.93% to $178017.0 in 2023, then surged by 6849.53% to $12.4 million in 2024, then soared by 284.99% to $47.6 million in 2025, then fell by 1.53% to $46.9 million in 2026.
- According to Business Quant data, Cost of Revenue over the past three periods registered $46.9 million, $47.6 million, and $54.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | 1.99 Bn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 673.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 2.55 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 99.50 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 2.30 Bn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 23.20 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 570.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Vireo Growth | 493.25 Mn | 350.95 Mn | 95.30 Mn | 114.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.90 Mn |
| Mar 31, 2026 | 46.90 Mn |
| Dec 31, 2025 | 47.63 Mn |
| Dec 31, 2025 | 47.63 Mn |
| Sep 30, 2025 | 54.27 Mn |
| Sep 30, 2025 | 54.27 Mn |
| Jun 30, 2025 | 27.65 Mn |
| Jun 30, 2025 | 27.65 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Dec 31, 2024 | 12.37 Mn |
| Dec 31, 2024 | 12.37 Mn |
| Sep 30, 2024 | 239,932.00 |
| Sep 30, 2024 | 239,932.00 |
| Jun 30, 2024 | 189,946.00 |
| Jun 30, 2024 | 189,946.00 |
| Mar 31, 2024 | 222,014.00 |
| Mar 31, 2024 | 222,014.00 |
| Dec 31, 2023 | 178,017.00 |
| Dec 31, 2023 | 178,017.00 |